HER2/Neu-positive Breast Cancer
2 clinical trials · Condition
◉ Watch HER2/Neu-positive Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer (NCT00496366) | Rutgers, The State University of New Jersey | 2007-07-23 |
Track HER2/Neu-positive Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.